This page in English

Sean Rudd

Postdoc

Om mig

Postdoctoral Research Fellow in the laboratory of Thomas Helleday

Utbildning

2013 - PhD in Biochemistry, Genome Damage & Stability Centre, University of Sussex, UK

2008 - BSc (Hons) in Biochemistry, University of Manchester, UK

Forskningsbeskrivning

My research centres upon the interplay between DNA precursor metabolism and genome stability, and how this can be exploited to enhance existing cancer therapies. Currently, my research is focused upon the enzyme SAMHD1, which we identified as a barrier to the efficacy of several antimetabolite-based cancer therapies.

 

For further reading see selected publications:

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

Pathways controlling dNTP pools to maintain genome stability.

Pedagogiska meriter

Main supervisor for MSc students

Co-supervisor for PhD student

Akademiska priser och utmärkelser

The Swedish Childhood Cancer Foundation Postdoctoral Fellowship

EMBO Long-Term Fellowship

Publikationer

SAMHD1 is a barrier to antimetabolite-based cancer therapies
Rudd Sg, Schaller T, Herold N
Molecular & cellular oncology 2017;4(2):e1287554-

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites
Herold N, Rudd Sg, Sanjiv K, Kutzner J, Bladh J, Paulin Cbj, et al
Cell cycle (Georgetown, Tex.) 2017;16(11):1029-1038

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Herold N, Rudd Sg, Ljungblad L, Sanjiv K, Myrberg Ih, Paulin Cb, et al
Nature medicine 2017;23(2):256-263

With me or against me: Tumor suppressor and drug resistance activities of SAMHD1
Herold N, Rudd Sg, Sanjiv K, Kutzner J, Myrberg Ih, Paulin Cbj, et al
Experimental hematology 2017;52():32-39

hMYH and hMTH1 cooperate for survival in mismatch repair defective T-cell acute lymphoblastic leukemia
Eshtad S, Mavajian Z, Rudd Sg, Visnes T, Boström J, Altun M, et al
Oncogenesis 2016;5(12):e275-

Pathways controlling dNTP pools to maintain genome stability
Rudd Sg, Valerie Nck, Helleday T
DNA repair 2016;44():193-204

Validation and development of MTH1 inhibitors for treatment of cancer
Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2016;27(12):2275-2283

Human PrimPol is a highly error-prone polymerase regulated by single-stranded DNA binding proteins
Guilliam Ta, Jozwiakowski Sk, Ehlinger A, Barnes Rp, Rudd Sg, Bailey Lj, et al
Nucleic acids research 2015;43(2):1056-68

PrimPol-A new polymerase on the block
Rudd Sg, Bianchi J, Doherty Aj
Molecular & cellular oncology 2014;1(2):e960754-

PPL2 translesion polymerase is essential for the completion of chromosomal DNA replication in the African trypanosome
Rudd Sg, Glover L, Jozwiakowski Sk, Horn D, Doherty Aj
Molecular cell 2013;52(4):554-65

PrimPol bypasses UV photoproducts during eukaryotic chromosomal DNA replication
Bianchi J, Rudd Sg, Jozwiakowski Sk, Bailey Lj, Soura V, Taylor E, et al
Molecular cell 2013;52(4):566-73

WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line
Goodfellow Sj, Rebello Mr, Toska E, Zeef La, Rudd Sg, Medler Kf, et al
The Biochemical journal 2011;435(1):113-25

Visa alla publikationer

Karta